Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Will Cut Manufacturing Sites As It Looks For More Baxalta Synergies

Executive Summary

Shire had a combined 17 manufacturing plants after the Baxalta merger, but plans to cut that to a total of 12. Manufacturing issues hit sales of its HAE drug Cinryze in the third quarter, and the firm is losing Lialda sales faster than expected.

You may also be interested in...



Shire Touts Ongoing Xiidra Growth, Targets Increased Medicare Access

Company outlines manufacturing streamlining and efficiency effort that it expects to add significant cost savings above synergies anticipated from merger with Baxalta.

Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze

With Haegarda holding a convenience edge over Cinryze for HAE prophylaxis, Shire now has data showing that SHP616 also offers significant prevention of HAE attacks. How ‘616 fits into Shire’s overall HAE strategy is unclear.

Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger

Shire's CEO says he sees scientific and technological advances as an opportunity to become the leading rare disease company. Ornskov also talked about the firm's debt-reduction and M&A strategy going forward.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel